RxDoctor Payments Data

Katherine Alexander

Nurse Practitioner · Columbus, OHNPI 1568879435

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $65,120 of the $99,494 with a category attached, or 65.5%. 60 manufacturers reported payments, led by Taiho Oncology, Inc. at 35.6% of the total. Reporting peaked in 2022 at $32,770 and has fallen 94.8% since, to $1,713 in 2025. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$99,494in general payments, 2019–2025

Across 641 payments — averaging $155.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Taiho Oncology, Inc.$35K
  • E.r. Squibb & Sons, L.L.C.$17K
  • Heron Therapeutics, Inc.$11K
  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • Pfizer$7K
  • Seagen Inc.$5K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$3,1313%
  • Speaking & faculty fees$65,12065%
  • Travel & lodging$15,97716%
  • Food & beverage$13,77714%
  • Education$1,4881%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Taiho Oncology, Inc.80$35,419
E.r. Squibb & Sons, L.L.C.55$16,629
Heron Therapeutics, Inc.18$11,154
Takeda Pharmaceuticals U.S.A., Inc.28$7,201
Pfizer21$6,539
Seagen Inc.24$5,436
Astellas Pharma US Inc18$4,944
BTG International Inc.1$1,000
AstraZeneca(2 entities)30$976
Eisai Inc.33$840
Incyte Corporation20$792
CTI Biopharma Corp.3$738
GSK17$685
Gilead(2 entities)24$634
Amgen13$501
Novartis28$500
Beigene USA, Inc.19$470
Daiichi Sankyo Inc.13$359
Merck13$327
Lilly USA, LLC11$284
Karyopharm Therapeutics Inc.9$274
Pharmacyclics LLC, An Abbvie Company11$264
Genentech USA, Inc.15$261
Bristol Myers Squibb14$245
Regeneron Healthcare Solutions, Inc.9$211
AVEO Pharmaceuticals, Inc.6$210
Jazz Pharmaceuticals Inc.3$194
Sobi, Inc4$181
Beone Medicines USA, Inc.3$180
AbbVie7$168
Ipsen Biopharmaceuticals, Inc7$166
Johnson & Johnson7$152
Array Biopharma Inc7$142
Tersera Therapeutics LLC6$141
Geron Corporation4$129
Coherus Oncology, Inc.3$98
Genmab U.S., Inc.5$89
Pharmacosmos Therapeutics Inc.5$85
Servier Pharmaceuticals LLC4$75
EMD Serono, Inc.4$74
Stemline Therapeutics Inc.3$72
Amneal Pharmaceuticals LLC3$69
Sanofi3$55
G1 Therapeutics, Inc.3$51
Blueprint Medicines Corporation3$49
Springworks Therapeutics, Inc.2$48
Exelixis Inc.2$45
ADC Therapeutics America, Inc.3$43
Pharmaessentia USA Corporation2$41
Kyowa Kirin, Inc.2$28
Tempus AI, Inc1$25
Bayer1$22
Dendreon Pharmaceuticals LLC1$21
Sun Pharmaceutical Industries Inc.1$21
Agios Pharmaceuticals, Inc.1$18
Spectrum Pharmaceuticals Inc.1$17
Acrotech Biopharma Inc.1$17
Boehringer Ingelheim1$17
Acceleron Pharma, Inc.1$16
AMAG Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,494 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$17,704
Medicare patients
124
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib19$288,900
TasignaNilotinib Hcl17$231,936
TagrissoOsimertinib Mesylate11$186,961
Oxycodone Hcl62$1,818
Hydroxyurea32$948
Letrozole31$769
Tamoxifen Citrate18$730
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$547
Morphine Sulfate23$414
Anastrozole16$370
Morphine Sulfate ErMorphine Sulfate20$345
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$312
Dexamethasone14$296
Gabapentin17$196
Prochlorperazine Maleate12$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$264$288,90019 claims
NovartisTasigna$500$231,93617 claims
AstraZenecaTagrisso$976$186,96111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$69$3712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →